Revolution Medicines, Inc. - Common Stock (RVMD)

Historical Holders from Q1 2020 to Q3 2025

Symbol
RVMD on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
186M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
192M
Holdings value
$8.95B
% of all portfolios
0.015%
Grand Portfolio weight change
+0%
Number of holders
315
Number of buys
176
Number of sells
-135
Average Value change %
+0%
Average buys %
+0.003%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Revolution Medicines, Inc. - Common Stock (RVMD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 7.9% +15.7% $512M $74.5M 13.3M +17% Dapice Joshua J. 31 Dec 2024
JANUS HENDERSON GROUP PLC 6.1% +6.67% $530M $35.7M 11.4M +7.23% JANUS HENDERSON GROUP PLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 5.5% $395M 10.3M Wellington Management Group LLP 30 Jun 2025
FMR LLC 5% $439M 9.4M FMR LLC 30 Sep 2025
BAKER BROS. ADVISORS LP 5% $361M 9.36M Baker Bros. Advisors LP 30 Jun 2025
BlackRock, Inc. 4.5% $309M 8.4M BlackRock, Inc. 30 Jun 2025

Institutional Holders of Revolution Medicines, Inc. - Common Stock (RVMD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 192M $8.95B +$87.5M $46.70 315
2025 Q2 191M $7.02B -$4.13M $36.79 305
2025 Q1 191M $6.78B -$112M $35.36 281
2024 Q4 193M $8.45B +$672M $43.74 278
2024 Q3 171M $7.74B +$69.5M $45.35 252
2024 Q2 168M $6.54B +$309M $38.81 221
2024 Q1 161M $5.17B +$42M $32.23 207
2023 Q4 160M $4.59B +$1.17B $28.68 183
2023 Q3 112M $3.11B +$13.4M $27.68 165
2023 Q2 112M $2.99B +$107M $26.75 138
2023 Q1 108M $2.34B +$421M $21.66 149
2022 Q4 88.3M $2.1B +$32.7M $23.82 133
2022 Q3 88.4M $1.74B +$234M $19.72 133
2022 Q2 76.5M $1.49B +$41M $19.49 125
2022 Q1 74M $1.89B +$15.8M $25.51 122
2021 Q4 73.3M $1.85B -$50.1M $25.17 113
2021 Q3 69M $1.9B +$49.8M $27.51 109
2021 Q2 70.4M $2.23B +$91.6M $31.74 127
2021 Q1 66.5M $3.05B +$424M $45.88 124
2020 Q4 57.4M $2.27B +$134M $39.59 118
2020 Q3 57M $1.98B +$340M $34.80 90
2020 Q2 46.9M $1.48B +$22.8M $31.57 73
2020 Q1 46.9M $1.03B +$1.02B $21.91 72